Ki­nase in­hibitor spe­cial­ist Kin­nate launch­es Shang­hai sub­sidiary with $35M to mar­ket its pro­grams in Chi­na

A lit­tle more than five months af­ter go­ing pub­lic with a $276 mil­lion IPO, Kin­nate Bio­phar­ma is back rais­ing mon­ey — this time for a new sub­sidiary launch­ing in Chi­na.

The yet-to-be named com­pa­ny is launch­ing Thurs­day with a $35 mil­lion Se­ries A round, Kin­nate said, and it will be a joint ven­ture with some of Kin­nate’s pre­vi­ous in­vestors. Or­biMed Asia Part­ners, Or­biMed Pri­vate In­vest­ments and Fore­site Cap­i­tal are all help­ing es­tab­lish the com­pa­ny, with Kin­nate tak­ing the role as ma­jor­i­ty stake­hold­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER